

12 MARCH 2026

SB2 Investment Report & NTA Update

| NTA PRE TAX | NTA POST TAX | TOTAL DIVIDENDS |
|----------------|----------------|-----------------|
| \$0.967 | \$1.044 | \$0.04 |

NET TANGIBLE ASSET VALUE PER SHARE AS AT 28TH FEBRUARY 2026

SB2[#] Portfolio Performance to 28th Feb 2026[†]

| 1 Month | 3 Months | 1 Year | 3 Year (p.a.) | Since Inception (p.a.) [^] | Since Inception [^] |
|---------|----------|--------|---------------|-------------------------------------|------------------------------|
| -5.01% | -3.24% | -5.95% | 2.71% | 2.79% | 13.95% |

[#] Salter Brothers Emerging Companies Limited ACN 646 715 111 (ASX:SB2)

[†] Portfolio performance is calculated net of Management fees but before taxes, other fees, and expenses. Performance has not been grossed up for franking credits received by shareholders.

[^] Inception date is 27 May 2021.

Summary

| | |
|--|----------|
| ASX Code | SB2 |
| Net Tangible Assets | \$87.78m |
| SB2 Market Capitalisation | \$63.06m |
| Share Price | \$0.75 |
| Discount to NTA | -28.16% |
| Companies Held | 33 |
| Weighted Average Market Cap of Portfolio | \$324m |
| Annualised Dividend Per Share | 4c |
| Annualised Dividend Yield % | 5.33% |

Performance



Pre-Tax NTA, Emerging companies index (ASX:XEC) and All ordinaries (ASX:XAO) have all been rebased to 0.80. Source Iress.

Portfolio Commentary

The portfolio declined 5.01% in February, as small industrials and ASX all tech decreased 4.8% and 8.8% respectively.


The reporting season was marked by heightened volatility and irregular market movements. Technology continued to underperform the broader market as investor sentiment continued to decline, which was exacerbated with increased tension from the middle east.

During the month portfolio performance was partially supported by the exit of two unlisted holdings.


The Directors declared a 2c per share fully franked interim dividend during the month of February that will be paid in April.

 A copy of the Salter Brothers external ratings report is available at www.salterbrothers.com.au/ratings-awards

Listed Portfolio Sector Weights



Portfolio Composition



The portfolio's investment strategy was compliant with the emerging companies' investment requirements of the Australian Significant Investor Visa regime for the period ending 28th February 2026.

Feature Stocks



IPSI

In the December quarter of 2022, the Salter Brothers Equities team established and was the lead investor for a special purpose vehicle (SB SPV No.1 Pty Ltd) created to acquire and restructure IPSI.

Over the subsequent three years, IPSI evolved into a scalable, enterprise-grade payments infrastructure platform aligned with regulatory developments and growing merchant demand for intelligent payment optimisation. Customer relationships deepened, product capabilities advanced and the commercial pipeline strengthened.

During February 2026, IPSI was sold to the Commonwealth Bank of Australia (CBA) at a significant uplift to the initial cost of investment and prior carrying value of the investment in the asset value of the Fund.

Environmental Group Ltd (ASX:EGL)

After monitoring EGL's progress for several years, the fund initiated its first investment in February. EGL provides environmental engineering solutions that help industrial customers reduce emissions, improve energy efficiency and treat waste streams.

The company reported a solid 1H26 result with revenue increasing 8.6% to \$58.9m and EBITDA growing 25.9% to \$4.9m. The Waste division continues to progress on its PFAS extraction technology, with a large-scale plant now installed and undergoing commissioning.

EGL maintained FY26 guidance for EBITDA growth of 15–20%, supported by a growing base of recurring revenue across the group.

PYC Therapeutics Ltd (ASX:PYC)

PYC completed a ~\$653m capital raise in February, increasing cash on balance sheet to ~\$750m, providing runway through to ~CY2030. Materially derisking PYC as it approaches several key readouts expected in CY2026 and CY2027.

The capital raise was oversubscribed and attracted strong support from leading US specialist life sciences funds. Their participation provides external validation on the clinical pipeline whilst also enhancing strategic credibility.

While the raise was larger than initially expected, the strengthened financial position removes funding risk and provides a strong backstop to valuation as the company progresses its clinical programs.

Top 5 Holdings

1. WRKR Ltd (ASX:WRK)
2. BETR Entertainment Ltd (ASX:BBT)
3. Symal Group Ltd (ASX:SYL)
4. PYC Therapeutics Limited (ASX:PYC)
5. Alfabs Australia Limited (ASX:AAL)

Metrics of the Listed Portfolio**

| | FY25A | FY26F | FY27F |
|-----------------------------|-------|-------|-------|
| Key Ratios | | | |
| EV / EBITDA (x) | 7.0x | 6.3x | 5.5x |
| EV / EBIT (x) | 11.1x | 9.9x | 7.9x |
| P / E (x) | 13.4x | 12.1x | 10.3x |
| Portfolio Financials | | | |
| Revenue Growth (%) | 19% | 25% | 20% |
| EBITDA Margin (%) | 10% | 8% | 12% |
| EBIT Margin (%) | 3% | 0% | 6% |
| NPAT Margin (%) | 0% | -2% | 4% |

**All metrics reflect weighted averages of the combined portfolio based on SB2 forecasts, as at 28/02/2026, adjusted for abnormalities and key ratios earnings metrics exclude loss making entities.

Key Listed Contributors & Detractors

Key Contributors for February 2026

| # | Company Name | Price Chg. (%) (Absolute) | Weighted Avg. Price Chg (%) |
|---|---|---------------------------|-----------------------------|
| 1 | Environmental Group Ltd (ASX:EGL) | +10.9% | +0.24% |
| 2 | BETR Entertainment Ltd (ASX:BBT) | +2.0% | +0.19% |
| 3 | Cash Converters International Ltd (ASX:CCV) | +4.7% | +0.14% |

Key Detractors for February 2026

| # | Company Name | Price Chg. (%) (Absolute) | Weighted Avg. Price Chg (%) |
|---|-------------------------------------|---------------------------|-----------------------------|
| 1 | Alfabs Australia Ltd (ASX:AAL) | -37.1% | -3.17% |
| 2 | Ai-Media Technologies Ltd (ASX:AIM) | -43.4% | -2.8% |
| 3 | WRKR Ltd (ASX:WRK) | -15.6% | -1.66% |

About Salter Brothers Emerging Companies Limited

ASX:SB2 is an actively managed Australian small caps investment portfolio that seeks to provide investors with attractive risk adjusted returns over the long term. Investing in listed and unlisted emerging companies (sub \$500m market cap) across a range of sectors.

About Salter Brothers

Salter Brothers is an Australian-owned global alternatives investment manager, with offices and operations in Australia, Singapore, Japan and the USA. It is focused on real estate, equities and private credit, with group assets under management of over A\$5.4 billion.

To find out more about Salter Brothers visit salterbrothers.com.au

Investment Team



Gregg Taylor
Investment Director



Emily Mohan
Investment Director



Francis Crossle
Analyst



Dane Grant
Analyst

Important - General information and Disclaimer

This information contained in this document has been prepared by Salter Brothers Funds Management Pty Ltd ACN 608 295 683 (**Manager**), a corporate authorised representative of Salter Brothers Asset Management Pty Ltd ACN 119 833 760 (AFSL 308 971) (**SBAM**) and Salter Brothers Emerging Companies Limited ACN 646 715 111 (**SB2**) (the Manager and SB2 are collectively known as the **Disclosers**).

The information contained in this document is general in nature and not intended to constitute financial product, investment, accounting, financial, legal or tax advice. It has been prepared without taking into account any person's objectives, financial situation or needs. Each recipient of this information should determine its interest in any opportunity presented, including any investment in SB2, on the basis of all independent investigations that it considers necessary or desirable, and should obtain its own legal, financial, taxation and other professional advice regarding this information before making a decision based on this information.

This document should be read in conjunction with SB2's other periodic and continuous disclosure announcements lodged with the ASX, which are available at www.asx.com.au.

This document is not a prospectus, disclosure statement or other form of disclosure document under the *Corporations Act 2001* (Cth) or any similar or analogous document in any other jurisdiction. It is for information purposes only and should not be considered as an offer or invitation to apply for or purchase any shares or other securities, or as an inducement to make an offer or invitation with respect to shares or securities, in any jurisdiction.

All investments, including any investments in SB2, are subject to risks. No guarantee or assurance is given by the Disclosers or any of their respective related bodies corporate or their respective officers or representatives in relation to the performance of SB2 or that any specific rate of return will be achieved or that there will be no loss of capital invested.

Unless otherwise stated, statements made in this document are made only as at the date of this document. The information in this document is subject to change without notice. Past performance is provided for illustrative purposes only and should not be relied upon – it is not indicative of or a guarantee of future performance.

To the extent that any forward looking statements are made in this document, those statements reflect the views of the Disclosers as at the date of this document. Such

statements involve known and unknown risks, uncertainties, assumptions and other important factors that could cause the actual results, performance or achievements of SB2 to differ materially from the results, performance or achievements expressed, implied or projected in this document. None of Disclosers or any of their respective officers or any other party associated with the preparation of this document: (a) make any representation or warranty (either express or implied) in relation to any forward looking statement or any events or results (either expressed or implied) in any forward looking statement, and recipients are cautioned not to place undue reliance on these statements; or (b) guarantee that any specific objective or forecast contained in this document will be achieved.

While care has been taken in preparing the information in this document, no representation or warranty, express or implied, is made as to the currency, accuracy, reliability, materiality, completeness or fairness of the information, opinions and conclusions contained in this document. The information in this document has been obtained from, or is based on, sources believed by the Disclosers to be reliable.

This document and its general disclaimer may be translated into languages other than English. Translation may be undertaken by a third party, and no guarantee can be made that such a translation will be complete or correct. In the case of any conflict between the different versions of this document and its disclaimer, the English version will prevail.

To the maximum extent permitted by law, the Disclosers, SBAM, their related bodies' corporate and each of their respective, directors, partners, advisors, officers and affiliates (**Representatives**) expressly disclaims any and all liability (whether direct, indirect, consequential or contingent), including, without limitation, any liability arising out of fault or negligence on the part of any person, for any loss, expenses, damages or costs arising from the use of information contained in this document including representations or warranties or in relation to the accuracy or completeness of the information, statements, opinions or matters, express or implied, contained in, arising out of or derived from, or for omissions from, this document including, without limitation, any financial information, any estimates, projections, forecasts or forward-looking statements and any other derived financial information. Anyone proposing to rely on or use such information should independently verify and check the accuracy, completeness, reliability and suitability of the information and should obtain independent and specific advice from appropriate professionals or experts.

Stay informed

Please subscribe to our newsletter and follow us on our social channels for market updates, results and webinars presented by our investment experts.

E | info@salterbrothersemergingcompanies.com.au
P | 03 9258 2100
W | www.salterbrothers.com.au

Authorised for release by the Board of SB2.



Visit the
SB2 Website

